BACKGROUND
Although the eukaryotic cytosolic chaperonin containing TCP1 (CCT) is the most complex of the group II chaperonins, it is evolutionarily conserved and found in all eukaryotes (2) . Figure  1 shows CCT's subunits each with a different color from a top view ( Figure  1A) , and a side view ( Figure  1B  &  C) . The structure of CCT remained unresolved for many years due to instability of the complex. Early cryo---EM experiments demonstrated that the two hetero---octameric rings of CCT formed the typical cylindrical shape, but the resolution was not sufficient to observe secondary structures (8) . An early model of CCT shows the different domains form the inner cavity, but incorrectly places the hetero---octameric rings stacked directly on top of one another ( Figure  1D ). More recent models have been refined using data from cryo---EM and X---ray crystallography studies at greater resolution to show an inter---ring misalignment that relates the upper and lower ring by a pseudo---two---fold symmetry (1)( Figure  1E ). Figure  1E also illustrates two tubulin substrate molecules in the inner cavity (magenta and lime green). The molecular diversity in the subunit composition of CCT gives rise to a more specialized role in protein folding than the general, nonspecific mechanism that is seen in other chaperonins. Substrate recognition is accomplished by the apical domains ( Figure  1D ), which are highly flexible and undergo large conformational changes during the functional cycle. In the open conformation, the apical domains allow substrates to enter into central cavity. Nucleotide binding at the equatorial domain occurs once substrate is bound and ATP hydrolysis triggers the conversion from the open to the closed conformation (1) . The exact mechanism has not been clearly defined, but is thought to involve a set of sequential, hierarchical steps.
It has been estimated that CCT may fold up to 10% of newly synthesized cytosolic proteins (3), so it plays an essential role in eukaryotic cellular function. Because CCT substrates are very diverse in function as well as structure, they cannot be predicted by homology alone (5) . Some of the proteins that have been shown to depend on CCT for their biogenesis include cytoskeletal proteins (α---, and β---actin, α---, β---, and γ---tubulin), histone deacetylases (HDAC3, Set3p, and Hos2p), cell cycle regulators (Cdc20p, and Cdc55p), and proteins possessing a seven---bladed β---propeller (WD40 repeat motif) (4, 5) , such as the β---subunit of heterotrimeric guanine nucleotide---binding proteins (G---proteins). A model of Gβ biogenesis and assembly into the heterotrimeric G---protein complex at the plasma membrane. 1. Nascent Gβ is folded by CCT with the help of the phosducin---like protein (PhLP) co---chaperone (9, 10). 2. All Gβ subunits irreversibly associate with Gγ soon after biogenesis and exist as dimers, with the exception of the Gβ5 subunit. It is not clear when, but at some point PhLP dissociates and the Gβγ dimer is formed. 3. Gγ becomes farnesylated or geranylgeranylated, which anchors Gβγ to the membrane, and is then targeted to the cytoplasmic surface of the endoplasmic reticulum (ER). 4 . Details of Gα biogenesis are still unclear, but it becomes either palmitoylated or myristoylated to anchor it to the membrane. 5. It is speculated that Gα associates with Gβγ at the ER and 6. the heterotrimeric G---protein complex is subsequently trafficked to the plasma membrane (11) .
PhLP1 is the most well studied studied of this family. Cryogenic Electron Microscopy (Cryo---EM) studies have shown that PhLP is not a substrate of CCT. Instead, PhLP interacts with CCT's apical domains on the top of the complex without any part of its mass entering the folding cavity ( Figure  3 ). These studies have also shown that PhLP can interact with CCT in a one to one ratio and can interact with any of CCT's subunits to assume one of two conformations (18) .
Although there has been extensive research into G---protein signaling, there are still many gaps in our understanding of G---protein biosynthesis. Because there are currently there are no available structures of this complex, nor is there a single published structure of PhLP I have used a homology modeling approach to generate the first known 3D structure of PhLP. The information that is gained from these structure---based studies can be combined with what is known from biochemical studies in order to gain isight into the interaction between PhLP and Gβ. Using this information I can make predictions to refine the mechanism of Gβ biosynthesis.
CHAPTER 1: THE ROLE OF CCT IN G-PROTEIN ASSEMBLY

Introduction
Initially most of the G---protein research had focused on Gα, leaving Gβγ largely ignored. However, more recent research has indicated that because of Gβ's unique structure, it is able to interact with a wide variety of other proteins and plays a very important role in cell signaling. Structurally, Gβ is a circular molecule composed of seven β---propeller WD40 repeats and belongs to the large family of WD40 proteins (23) . Like other WD40 proteins, Gβγ is able to interact with a wide variety of proteins. X---ray crystallography of Gβ co---crystalized with its binding partners has revealed that all of Gβ's binding partners share a common interface (Figure  4) . A recent review conducted on the structural interaction of Gβγ with its binding partners suggests that each protein interacts with Gβγ through a unique combination of residues within the common binding surface (24) . This region of multi---target recognition called a "hot spot", is a region on the protein surface that is structurally flexible enough to accommodate multiple modes of binding (24) . This interface is also the point of interaction between Gα and Gβγ ( figure  4D ). Heterotrimeric G---protein signaling begins with dissociation of Gα---GTP from the Gβγ dimer. While Gα subunit signaling is terminated by hydrolysis of GTP, Gβγ signaling must be terminated by re---association with Gα subunits or in a way that blocks the binding surface of Gβ. The re---association of the G---protein α---, β---, and γ---subunits into the inactive heterotrimeric G---protein complex is a critical point in the regulation of overall G---protein signaling activity.
Phosducin---like protein (PhLP) plays an important role in Gβ biosynthesis, but the mechanism is not well understood. Our current understanding of this process was summarized by Willardson and Howlett in 2007 ( Figure  5 ) (12) . As a nascent Gβ emerges, it forms a ternary complex by entering into the folding cavity of CCT and binding to PhLP and. It is not clear whether Gβ associates with PhLP before or after entering CCT, but the interaction is controlled by PhLP because over---expression of PhLP decreases the binding of Gβ to CCT (25) . In this model it is theorized that the purpose of PhLP is to pull the folded Gβ out of CCT and direct it to the membrane where it can associate with Gα. It is also thought that this mechanism is regulated by phosphorylation of PhLP. Phosphorylation of residues S18---20 by casein kinase 2 (CK2) is predicted to destabilize the ternary complex so that PhLP and the folded Gβ can be released (25) .
Experiments involving the truncated splice variant of phosducin---like protein (PhLP), referred to as PhLPSHORT (PhLPs) (19) , have provided additional information that seems to support this mechanism. Despite having a significantly reduced affinity for Gβ (14, 21) , PhLPs is still able to inhibit CCT in a dominant negative fashion (20, 25) , Immunoprecipitation (IP) experiments utilizing transgenic mice expressing PhLPs---FLAG (Tg+) in photoreceptors indicate that PhLPs is still able to interact with CCT ( Figure  7A ). The additional presence of the transducin β---subunit (Gβ1) in the IP suggests that the trimeric PhLP(s)---CCT---Gβ1 complex forms but cannot separate, leaving Gβ trapped inside CCT ( Figure  7B ). This supports Willardson's model because the N---terminal residues that PhLPs lacks contain the residues implicated in CK2 phosphorylation as well as Gβ binding. However, there are still many details of this mechanism that are unclear.
In order to gain a better understanding of the involvement of PhLP in Gβ biosynthesis, I combined experimental data with structural information. Using homology modeling, I was able to construct a 3---dimensional model of PhLP based on the crystal structure of the closely related protein phosducin (Pdc). Then I docked the PhLP model to the crystal structure of Gβ1 to simulate binding. By identifying the residues involved in binding to Gβ, binding to CCT, and phosphorylation I demonstrate how PhLP is able to associate with both CCT and Gβ, and predict how phosphorylation of PhLP triggers the release of Gβ. Ultimately, this information may determine CCT's role in G---protein biosynthesis through its interaction with PhLP and Gβ.
Results
Generating a 3D structure of PhLP
In order to gain a better understanding of the role that CCT plays in G---protein biosynthesis, we must first figure out how the interaction between its co---chaperone, PhLP, and its substrate, Gβ. There are currently no published structures of PhLP. In order to determine how PhLP is interacting with Gβ, and to predict the mechanism of release I generated a 3D structure of PhLP based on homology modeling. Homology modeling is the most accurate and widely used method of protein structure prediction. It is based on the empirical observation that 3D structure is the most robustly conserved feature of homologous proteins. Even when the primary sequence has been altered by mutation, deletion, or insertions, the 3D structure of evolutionarily related proteins is largely preserved. Building a 3D model of an unknown "target" protein based on its primary amino acid sequence requires a closely related protein with a known 3D structure to act as a "template". There are different approaches to homology modeling, but they all follow four basic steps; 1) identify one or more proteins to serve as the 3D template, 2) sequence---structure alignment to line up amino acid residues of the target to the corresponding ones in the template, 3) use the sequence---structure alignment to generate a 3D model of the target protein, and 4) evaluate the model for correctness (Figure  7) .
The phosducin family of proteins is very small and the proteins are evolutionarily conserved from simple single cell eukaryotes to higher order mammals. Fortunately, the crystal structure of rat phosducin (Pdc) has been solved (26) . Phosducin and PhLP are both members of Subgroup II of the phosducin family, and both proteins have a high degree of similarity. To confirm that Pdc was the best protein to use as a template for mouse PhLP, the Position---Specific Iterative Basic Local Alignment Search Tool (PSI---BLAST) was used via the Internet---based PredictProtein (www.predictprotein.org) website. The sequence of mouse PhLP1 has 301 amino acids and rat Pdc has 246 amino acids. They share 65% similarity in primary amino acid sequence with 109 identical and 88 similar residues, making it the best template with a crystal structure. Two different 3D structures of rat Pdc were available through the Protein Data Bank (PDB = 1B9X, and 2TRC), and both were used as template molecules for homology modeling.
Sequence alignment and the generation of a 3D model of PhLP1 were accomplished using INSIGHTII, a graphical molecular modeling program developed by Accelrys Inc. (formerly a product of MSI and BIOSYM).
Using INSIGHTII, the amino acid sequence of PhLP was aligned to those of the two Pdc templates based coordinates obtained from their crystal structures. In order to confirm the sequence alignment and to determine how similar the structure of PhLP will be to Pdc, PredictProtein was used to predict the secondary structure, solvent accessibility and membrane helices. PredictProtein makes these predictions by combining results of the PHD and PROF servers in order to visually represent the likelihood of beta sheet or alpha helical secondary structures, disordered regions, and solvent accessibility occurring along the primary amino acid sequence (Figure  8 ). Secondary structure prediction was done for PhLP and Pdc individually and then compared back to the sequence---structure alignment generated by INSIGHTII ( Figure  10 ). PredicProtein accurately predicted the secondary structural features of Pdc. Based on these prediction, the C---terminal domain of PhLP is very similar to Pdc but there were two notable differences in the N---terminus. First, in PhLP Helix 2 is predicted to be closer to Helix 1 while in Pdc Helix 2 is adjacent to Helix 3. Secondly, the region of the N---terminus before Helix 1 is much longer in PhLP and is predicted to be disordered and solvent accessible.
. α-helix β-sheet Loop Solvent exposed Solvent exposed Loop β-sheet α-helix Generation of a 3D PhLP model was accomplished using the CONSENSUS module of INSIGHTII, using distance constraints derived from the reference protein structures (Figure  11 ). Superimposing the PhLP model onto the Pdc structure indicates the high degree of similarity between the two structures. In figure  11A Pdc is modeled by a light blue ribbon with the flexible N---terminus and the C---terminal thioredoxin domain indicated. The C---terminus of Pdc is rigid, but the N---terminus, which is composed of 3 α---helices (H1, H2, H3) is very flexible. Figure  11 B&C shows Pdc modeled by a dark blue ribbon and PhLP modeled by a green ribbon. The C---terminal thioredoxin domain is almost perfectly superimposed but, with the exception of H3, the N---terminal domain shows significant differences. Figure  11D shows the structure of PhLP in green with residues involved in Gβ binding predicted by homology to Pdc shown in light blue, residues involved in CCT binding in white, and phosphorylation sites in red. The N---and C---terminus are longer than that of Pdc, and are shown in figure 11 C&D to extend out away from the rest of the molecule. Figure  11 C&D suggests that portions of the N---terminus of PhLP are less disordered and exposed to solvent, but no conclusions can be drawn since there is no template for structure prediction. The red arrows in figure  11B&C point to the region on helix---1 that is critical for Gβ binding. These residues are conserved between PhLP and Pdc but since figure 11B indicates that they are not superimposed, it is likely that there are differences in Gβ binding. The white arrows in figure  11B ,C, and D point to a flexible loop that may be implicated in triggering the release of Gβ. The residues on PhLP that are involved in binding to CCT are shown in white in figure  11D . The flexible loop on the N---terminus of PhLP that is involved in CCT binding is not present in Pdc, which explains why phosducin is unable to bind CCT. Note that in Figure  11A only one α---helix connects the N---terminal domain of Pdc to the C---terminal domain, while in figure 11C PhLP has two connections (pink arrows). H3 connects the N---and C---terminal domains of both PhLP and Pdc. The second connection between the N---and C---terminus of PhLP is formed by residues on the N---terminus prior to H1. This suggests that PhLP is much less flexible than Pdc.
In order to determine how PhLP might interact with Gβ, I compared my model to the crystal structure of the Pdc---Gβ1γ1 complex (PDB = 2TRC). Initially, PhLP simply replaces Pdc in the Pdc---Gβ1γ1 complex to highlight the differences between the two proteins with respect to Gβ binding ( Figure  12 ). Gβ1γ1 is shown in yellow, Pdc is shown in light blue, and PhLP is shown in green. In Figure  12 A&B, Pdc makes three points of contact with Gβ1γ1. H1 is the most critical for binding, and H3 as well the residues on the C---terminal domain help to stabilize the complex. In comparison, PhLP seems to wrap around Gβ1γ1. In figure  12D the residues 1---83 of PhLP are colored in brown to illustrate the residues that are absent in PhLPs. These structures clearly indicate that PhLP does not interact with Gβ1γ1 in the same way as Pdc because the N---terminus is intertwined with Gβ. The red arrows in figures 12A&C indicate that the binding of Gβ to H1 of Pdc and PhLP may differ, which may affect the overall structure. In figures 12 C&D the residues of PhLP that interact with CCT are shown again in white, the residues that contact Gβ are in light blue, and residues 1---83 that are removed in PhLPs are
Discussion
Despite the similarity between phosducin and PhLP there are subtle differences in their structure. By combining the information that we have gathered from homology modeling with biochemical data we can speculate about PhLP's function in three different areas. First, these results help to explain how PhLP and PhLPs are both able to interact with CCT and Gβ simultaneously. The 3D model that I generated of PhLP shows that this is possible because the binding sites are distinct. Furthermore, the mechanism of CCT inhibition by PhLPs that was proposed by our lab ( Figure  6 ) is supported because neither the CCT nor the Gβ binding sites are perturbed in PhLPs. Second, they reveal important information about the interaction between PhLP and Gβ that is suggestive of its role in G---protein biosynthesis.
The mechanism of Gβ biosynthesis proposed initially proposed by Georgi Lukov and Barry Willardson in 2004 initially suggested that PhLP directly interacts will nascent Gβ and this interaction is stabilized by CK2 phosphorylation of PhLP (22) . This mechanism was later refined by Barry Willardson and Alyson Howlett in 2007 suggesting that nascent Gβ first binds to CCT, which then recruits PhLP (12) (Figure  4 ). In this later model, CK2 phosphorylation functions to release Gβ from CCT. The PhLP---Gβ complex then binds Gγ forming the PhLP---Gβγ complex. Finally, Gα replaces PhLP to form the heterotrimeric G---protein complex at the membrane. The first issue that remains to be resolved in this model pertains to the purpose of PhLP. Is PhLP required for the folding of Gβ by PhLP, to prevent Gβ from being released from CCT before it is properly folded, to stabilize the folded Gβ until it can be stabilized by Gγ, or any combination of those roles? The second issue is that although the evidence of CK2 phosphorylation causing release of PhLP---Gβ from CCT is well supported (25) , the mechanism by which Gβ is released by PhLP is still unclear.
Based on the 3D model that I generated of PhLP I have come up with a revised mechanism of PhLP's involvement in G---protein biosynthesis ( Figure  12 ). 1. Nascent Gβ enters the folding cavity after it is translated. PhLP does not require Gβ to bind CCT (18) . I believe that the first 50 amino acids in the long unstructured N---terminus of PhLP may help to weaken the interaction between PhLP and CCT. However, this is purely speculative because the structure of this region could not be determined. 2. Once Gβ enters the inner chamber of CCT it becomes partially folded, and 3. PhLP will be able to bind with higher affinity because there are more points of contact. I predict that the long unstructured N---terminus of PhLP pulls Gβ out of CCT after its folded. When PhLP binds to CCT and Gβ to form the tertiary complex, this strand becomes wedged in between Gβ and the C---terminal thioredoxin domain of PhLP, which has a net charge of ---19. Furthermore, I predict that when H1 of PhLP binds to Gβ it causes the N---terminal strand to rotate, exposing residues S18---20. 4. When these residues becomes phosphorylated by CK2 the charge repulsion causes PhLP's N---terminal strand to move away from the C---terminal domain, 6. effectively prying Gβ out of CCT's inner chamber.
I have also been able to make a prediction as to how and when Gβ is released from PhLP based on this model. Previous studies have shown that complexes of PhLP and Gβ were found that do not contain Gγ (22) , which supports PhLP's role in stabilizing Gβ before Gγ can bind and form the stable Gβγ dimer. From the model of the PhLP---Gβ1γ1 complex shown in figure  12C&D , it is clear that PhLP does not bind to Gβ like Pdc. The N---terminus of Pdc is flexible and can orient the rest of the molecule around Gβγ. In contrast, PhLP is more rigid and because of this I believe that PhLP and Gγ are mutually exclusive in their interaction with Gβ. I predict that the key to PhLP's release of Gβ can be found in the loop between H2 and H3 indicated by the white arrows in figure  10  and  figure  11 . The region of Gβ that is critical for its interactions with binding partners is located on the top of the torus created by the β propeller folds (24) . I predict that in the absence of Gγ, PhLP pinches the N---terminal α---helix of Gβ in toward the hydrophobic residues on the fifth β---propeller blade (WD5 in Figure  4A ). This functions to stabilize Gβ as well as hold it in a position to readily accept Gγ. The interaction between Gγ and Gβ is very strong. 7. Once Gγ comes in contact with Gβ it will push the N---terminal α---helix of Gβ away from WD5, causing PhLP to loosen its hold on Gβ. 8. At this point PhLP's affinity for Gβ will be so low that it will easily dissociate as Gγ becomes either farnesylated or gernylgernylated at the endoplasmic reticulum. Lastly, 9. Gβγ associates with Gα and 10. the heterotrimeric complex is trafficked to the plasma membrane. Figure  12 . Revised model of Gβ biogenesis based on prediction from the 3D structure generated of PhLP. 1. Nascent Gβ enters the folding cavity after it is translated. 2. Once Gβ enters the inner chamber of CCT it becomes partially folded, and 3. PhLP binds forming the tertiary complex and helps to complete the folding of Gβ. When H1 of PhLP binds to Gβ it also causes the N---terminal strand to rotate, exposing residues S18---20. 4. When these residues becomes phosphorylated by CK2 the charge repulsion causes PhLP's N---terminal strand to move away from the C---terminal domain, and 6. PhLP---Gβ disassociates from CCT. 7. PhLP primes Gβ for binding to Gγ. Once Gγ binds, it displaces PhLP reducing its affinity for Gβ. 8. PhLP's easily dissociate as Gγ becomes either farnesylated or gernylgernylated at the endoplasmic reticulum 9. Gβγ associates with Gα and 10. the heterotrimeric complex is trafficked to the plasma membrane.
Introduction
PhLP is alternatively spliced, resulting in the loss of the first 83 amino acids ( Figure  13 ). The truncated variant is referred to as PhLPSHORT (PhLPs) (19) , and while full length PhLP has ubiquitous expression, PhLPs is primarily found in the adrenal gland (19) . This truncation removes amino acid residues that are critical for binding to Gβ. Because of this, PhLPs has a much lower affinity for Gβ than PhLP (20) and binds Gβ very poorly (14, 21) . Despite the weak interaction with purified Gβ, PhLPs can still interact with and inhibit CCT (10). However, this interaction has also been shown to inhibit Gβγ signaling and protein expression in a dominant negative fashion (20, 22) . Because PhLPs is such a potent inhibitor of CCT, is commonly used as a tool in the lab to study CCT activity. In cells, PhLPs expression additionally causes inhibition of Gβγ signaling and a profound reduction of Gβγ protein expression (20, 22) . Since PhLPs does not interact with Gβ directly, the effects on G---protein expression are thought to be an indirect consequence of CCT inhibition (10) . In order to study the effect of CCT inhibition on G---protein signaling in vivo, our lab created several lines of mice that constitutively expressed PhLPs in rod photoreceptors. Photoreceptors in the eye are classically used for G---protein research due to the uniquely high concentration of a single type of G---protein referred to as transducin. Transducin is a heterotrimeric G---protein composed of transducin---α (Gtα1), transducin---β (Gβ1), and transducing---γ (Gγ1) subunits. While Gβ1 and Gγ1 are common to both rod and cone photoreceptors, Gtα1, is specific to rods. Because approximately 96% of mouse photoreceptors are rods, using rod photoreceptors allows us to conduct experiments in cells enriched in G---proteins.
Our lab had previously created three lines of transgenic mice that constitutively express PhLPs in order to study the effects of CCT inhibition in vivo. In these transgenic mice, expression of Δ1---83 PhLP (PhLPs) with a FLAG tag is under the control of a modified 4.4 kb rhodopsin promoter ( Figure  14A ). Beginning at age P5 in mice, the rhodopsin promoter becomes active and PhLPs---FLAG is expressed in the transgenic mice. The resulting mouse lines were confirmed by tail PCR genotyping methods to determine transgenic positive (Tg(+)), and transgeneic negative (Tg(---)) mice for each line. PhLPs protein expression levels were determined by immunoprecipitation (IP) with α---FLAG antibody and western blotted using rabbit anti---FLAG antibodies ( Figure  14B ). The resulting transgenic mouse lines had varying levels of PhLPs expression. Line 1178 is the "high expressor", 1054 is the "middle expressor", and 1065 is the "low expressor" of PhLPs. The level of PhLPs protein expression corresponded to a progressive loss in photoreceptors as seen from hemotoxylin and eosin staining of retinas ( Figure  14C ) and a loss in nuclei ( Figure  14D ) with a severity directly correlated with the level of PhLPs expression.
Western
is not surprising because without Gβ it will simply be degraded. However, the effect on Gtα1 was very unexpected. Gtα1 protein levels were so low that the fold change could not be quantified. The band seen in the blot for Gtα1 is non---specific ( Figure  14A ). Further analysis revealed that gene expression levels showed a similar reduction. While gene expression of Gβ1 (Gnb1) and Gγ1 (Gng1) was reduced by roughly half, Gtα1 (Gnat1) mRNA had a greater than 95% reduction ( Figure  14B ). Currently there is no known mechanism to explain the loss of Gtα1 expression. These findings represent the first known evidence of connecting the activity of chaperonin CCT to G---protein gene activity.
The focus of this chapter is on gaining a better understand of CCT's role in the regulation of G---protein signaling. We used a microarray to show that the inhibition of CCT does not result in a wide---spread reduction in gene expression. Instead, only a very small subset of genes are significantly affected. Because the expression of PhLPs in the constitutive mouse lines cannot be controlled, our lab also began developing lines of transgenic mice that have inducible expression of PhLPs (iPhLPs). The iPhLPs mice will allow we to express PhLPs in mature photoreceptors in order to determine if the inhibition of CCT affects a developmental process.
Results
Microarray Analysis
One possible explanation for the loss of Gtα1 at the protein and mRNA level due to PhLPs expression is that inhibition of CCT leads to loss of a transcription factor. In order to test this, the Affymetrix GeneChip Whole Transcript Exon Array was used to monitor the changes in mRNA expression in transgenic mice expressing PhLPs (Tg(+)) compared to littermate control mice (Tg (---) ). Exon Arrays are a high---density microarray platform with a total of ~6.5 million probes targeting all the annotated and predicted exons in the genome. A single gene on an Exon Array is assigned a set of 4 core probes targeted to each putative exonic region of a single gene, and collectively the probes representing the same gene are referred to as a "transcript cluster" (Figure  16A ). Retina samples were collected from each of the three constitutive mouse lines, 1178, 1054, and 1065 at P10. For each line, three Tg+ mice were compared against Tg---littermate controls ( Figure  16B ). The results of each chip were first background subtracted using the signal from a set of 37,687 genomic and antigenomic background probes that are not matched to any putative transcript region. The data was then normalized using GeneBASE Probe Effects, which multiplies the data by a scaling factor so that the median intensity of all core probes in an array equals 100 (Figure  17) .
Because some probes respond poorly to target signals, or cross---hybridize to non---specific gene targets, core probes must be chosen to accurately represent changes in gene expression. Using Probe Select in the Affy package of Bioconductor, we implemented the Li---Wong model for probe selection (27) The algorithm developed by Li and Wong seeks to identify the largest subset of highly correlated probes to represent a single gene. They reason that the majority of probes targeting constitutive exons of a particular gene will have a comparable intensity profile across various different tissues, and reflect the overall mRNA abundance of that gene. Therefore, we downloaded the mouse exon array tissue panel dataset from Affymetrix consisting of 11 tissues (breast, cerebellum, heart, kidney, liver, muscle, pancreas, prostate, spleen, testes, and thyroid) each with three replicates. For each gene we calculated the Pearson correlation coefficient of the signal intensities of all possible pairs of probes across the 11 tissues (a total of 33 samples) and used that to perform average---linkage hierarchical clustering, which is visualized on a heatmap using R (Figure  18 ). Hierarchical clustering of our retina samples across the entire tissue panel indicates that our retina samples correlates most closely with retina tissue samples. When the retina samples alone were analyzed, Tg+ samples clustered together and Tg---samples clustered for high and medium expressors (1178 and 1054). However, some of the positive samples from the low expressor line (1065) clustered with the Tg---samples. Since the 1065 Tg+ samples did not significantly differ from the Tg---samples, they were excluded from further analysis. This may be due to the fact that expression level of this line is so low that retina samples do not resemble those of the higher expressing lines until around P21. It is possible that samples from the low expressor 1065 line would cluster better if they were taken later.. Figure 18 . Probe correlation across Affymetrix Mouse Exon Array Tissue Panel. Retina samples from three positive and three negative mice from each of the transgenic PhLPs mouse lines at post-natal day 10 were compared to the mouse exon array tissue panel dataset from Affymetrix consisting of 11 tissues (breast, cerebellum, heart, kidney, liver, muscle, pancreas, prostate, spleen, testes, and thyroid) each with three replicates. Hierarchical clustering was used to group together arrays that show correlated gene expression.
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Genes expression from Tg(+) animals was compared to Tg(---) controls to identify genes that were affected by PhLPs. The change in gene expression was considered significant if the p---value was less than 0.05 and the change in expression was either greater than 1.5 or less than 0.5. For both the high (1178) and medium (1054) expressor lines, only 160 genes had a significantly different expression level in Tg+ samples. When all of the Tg+ samples were compared to all of the Tg---samples, only 8 genes had a greater than 1.5 fold increase, and 9 genes were decreased by 0.5 or more (Table  1) .
Microarray Validation
The results of the microarray were validated by quantitative Real Time PCR (qPCR). The microarray results show that Gtα1 was one of the genes that had been significantly decreased. In the combined analysis, it was reduced 0.2 fold, which is in agreement with previous qPCR results ( Figure  15 ). Primers for 6 genes were designed for qPCR validation based on the microarray results. Lrp4 (low density lipoprotein receptor---related protein 4), and Rabgef1 (RAB guanine nucleotide exchange factor (GEF) 1) were shown to be downregulated by the microarray and were chosen for validation. Lrp4 is a potential cell surface endocytic receptor, which binds and internalizes extracellular ligands for degradation by lysosomes. Rabgef1 stimulates nucleotide exchange on RAB5A and is involved in endocytic membrane fusion and membrane trafficking of recycling endosomes. Additionally, 3 genes, including Atf3 and two other genes that were shown to be upregulated based on microarray results were chosen, for the validation. Atf3 (activating transcription factor 3) binds the cAMP response element (CRE) sequence present in many viral and cellular promoters, and represses transcription from promoters with ATF sites. It is thought to repress transcription by stabilizing the binding of inhibitory cofactors at the promoter. Npas4 (neuronal PAS domain protein 4) is primarily expressed in the limbic system and olfactory bulb where it acts as a transcriptional activator to activate expression of the drebrin gene. Npas4 had a 2.4 fold increase in the high expressor line (1178), but was not found to be significant (p---value = 0.08) due to one low value in the medium expressor line (1054). Eif2ak3 (eukaryotic translation initiation factor 2 alpha kinase 3) was chosen because although the change in expression was found to be non---significant in the microarray (p---value = 0.0583), it had a 2.1 fold change and is involved in the unfolded protein response (UPR). It will be interesting to determine if some of the observed photoreceptor defects are due to UPR from inhibition of CCT.
The results from the qPCR validation are in general agreement with the results of the microarray ( Figure  20 ) because all of the genes show the same direction of expression change. However, there were some slight differences. The change in Lrp4 gene expression was not found to be significant (p---value = 0.056) due to variation in one Tg+ sample. It is expected that with a larger sample size (n > 3) the difference in expression level will be significant. Additionally, the increase in gene expression was found to be significant for Eif2ak3 (p---value = 0.009) and slightly significant for Npas4 (p---value = 0.048) in the qPCR validation despite have a non---significant difference shown in the microarray. Overall, these results indicate that genes from Tg+ samples showing greater than 1.5 or less than 2 fold change on the microarray are significantly different from Tg---samples, and the UPR may contribute to some of the photoreceptor degeneration. Gene Ontology (GO) analysis was performed to see what pathways or cellular functions were enriched based on the microarray results. Using the web---based on---line tool WebGestalt (WEB---based GEne SeT AnaLysis Toolkit), the genes that changed significantly in Tg+ animals were compared back to the annotated Affymetrix Mouse Exon Array 1.0 for enrichment analysis. The results from the WebGestalt enrichment analysis were organized into a "GO Tree", which is based on the GO DAG (Directed Acyclic Graph) in order to visualize enrichment categories, enriched gene numbers, and the statistical significance level (Figure  21 ). An enriched DAG shows GO categories with enriched gene numbers (in red) and their non---enriched parents (in black). Based on the microarray experiment, a total of 160 genes had significant expression changes in Tg+ samples from both the high (1178) and medium (1054) expressor lines. Of these genes, 55 had expression changes by 1.5 fold or more. These genes were organized into a GO Tree under 3 broad categories for biological process, molecular function, and cellular process.
The gene categories that were significantly enriched (p < 0.05) upon PhLPs expression fell under the 'biological process' subheading. A few categories that were similar were also made up of the same genes so All of the categories that most of the enriched GO categories identified for this gene set could be placed into one of five categories related to response to stimulus, phototransduction, eye and sensory organ development, membrane organization & endocytosis, and sensory/visual perception. Under the category 'response to stimulus' the genes Gngt1, Gnat1, and Rcvrn were also found in 'response to radiation', 'detection of abiotic stimulus', 'detection of external stimulus', 'detection of stimulus', 'response to light stimulus', 'response to abiotic stimulus', and 'phototransduction'. Similarly, the same three genes, Rpgrip, Gngt1, and Gnat1, make up the categories 'eye photoreceptor development', 'photoreceptor cell differentiation', 'photoreceptor cell development', 'eye development', 'neuron development'. In addition, the genes Lrp4, Abca1, Pla2r1, and Rabgef1 make up the 'endocytosis' category as well as 'membrane invagination', 'vesicle---mediated transport', and 'membrane organization'. Lastly, the 'sensory perception of light' and 'visual perception' categories were made up of the genes Pdcl, Rpgrip1, Rcvrn, Ush2a, Gucy2f, and Gnat1. Although 'spermatid development' was listed as a significantly enriched category, it is made up of only two genes, Dhh and Prm1. However, the significant upregulation in gene expression of Prm1 (protamine 1) that was shown in the microarray analysis may just be an artifact because the polyadenylation sequence of the transgene was derived from Prm1. Further validation tests using qPCR have indicated that the levels of Prm1 do not change significantly.
What is noticeably absent from the enrichment analysis is an involvement of genes in apoptotic or the UPR. Since the minimum number of genes required to show enrichment in a single category was only set to 2, it is unlikely that these pathways play a role in CCT's connection to G---protein expression. A few individual genes that appeared in many categories of the GO Tree analysis were Lrp4, Rabgef1, Rcvrn, Ush2a, and Rpgrip1. Lrp4 (low density lipoprotein receptor---related protein 4) and Rabgef1 (RAB guanine nucleotide exchange factor (GEF) 1) are both involved in membrane organization and invagination, and Lrp4 is also involved in cellular development. The Rcvrn (recoverin) gene encodes a member of the recoverin family of neuronal calcium sensors and is thought to prolong the termination of the phototransduction cascade in the retina by blocking the phosphorylation of photo---activated rhodopsin. Two very interesting genes are Ush2a (Usher syndrome 2A homolog) and Rpgrip1 (retinitis pigmentosa GTPase regulator interacting protein 1), which are both involved in photoreceptor development, visual perception, and cell projection. Usher syndrome is a genetic disorder that is characterized by deafness and progressive loss of vision. The three different types of Usher syndrome are thought to be responsible for 3 percent to 6 percent of all childhood deafness and about 50 percent of deaf---blindness in adults. Interestingly, the loss of vision is due to the eye disease, retinitis pigmentosa (RP), which causes photoreceptor degeneration. Although Ush2a expression was only increased by 0.64 fold (Table  1) , it is tempting to make a connection between CCT inhibition and gene expression changes that are seen in a progressive eye disease. Overall, these results support the role of CCT in G---protein expression and signaling because when CCT is inhibited by PhLPs, the genes involved in visual processing and photoreceptor development are significantly impacted. .
Inducible expression of PhLPs (iPhLPs)
In young mice, the expression of rhodopsin occurs around age P5 and triggers the development of rod photoreceptor outer segments. Inhibition of CCT during this critical period could affect specific molecular or signaling events related to development. A major limitation of the high (1178), medium (1054), and low (1065) expressor lines is the inability to control PhLPs expression. Expression of PhLPs in these lines began at P10 with the expression of rhodopsin. Because we could only identify the transcriptional CCT feedback in the underdeveloped photoreceptors of neonatal mice constitutively expression PhLPs we couldn't determine whether the inhibition of CCT might cause development changes. To overcome this limitation, transgenic models with the regulated tetracycline---dependent PhLPs expression have been developed in our laboratory in order to study the effect of CCT suppression on the Gtα1 gene (Gnat1) activity in retinas of adult mice.
We have developed six lines of transgenic mice that have tetracyclin---inducible PhLPs expression (iPhLPs) to allow us to study the effect of CCT suppression on Gnat1 activity in retinas of adult mice. These mice were generated by crossing transgenic TRE---Tight---Δ1---83 PhLP---FLAG mice (expressing PhLPs), with mice containing a reverse tetracycline---dependent transactivator (rtTA) under the control of an opsin promoter. The result of this cross is a mouse line carrying both the TRE---Tight---Δ1---83 PhLP---FLAG as well as the rtTA transgene ( Figure  22A ). After age P5 rtTA is continuously produced in retinal photoreceptor cells where the opsin promoter is active. In order for the TRE---Tight promoter to become active, it must be bound by both rtTA and tetracycline. Therefore, in this inducible model administration of the tetracycline analog, doxycycline, drives PhLPs expression specifically in photoreceptor cells.
Several lines of iPhLPs were generated and tested for PhLPs expression by FLAG immunoprecipitation (IP) and western blotting for α---FLAG. Out of these lines, two lines (line 2339 and 2347) were chosen for further experimentation because they had the highest level of PhLPs expression. Mice from these lines were genotyped to identify individuals that were positive for the iPhLPs transgene. These PhLPs positive mice were then given doxycycline to induce expression of PhLPs in retinal photoreceptors. Initially, doxycycline was administered through drinking water at either 1.0 or 10 mg/ml for 10 days, but there was some variability in PhLPs induction. In order to reduce the variability, all mice were given 10 mg/ml doxycycline + 50 mg/ml sucrose in their drinking water for 1, 3, or 9 days ( figure  22B  upper  panel) . Because PhLPs expression remained highly variable and occurred with low frequency, 0.1 ml doxycycline (10 mg/ml) was administered by intraperitoneal injection every 24hrs for two days ( figure  22B,  lower  panel) . Despite the efforts to standardize the amount of doxycycline that each animal received, the individual variability in PhLPs expression even among littermates remained high.
In order to test whether PhLPs induced CCT inhibition in adult mice has the same effect on G---protein levels in mice at P10, the levels of Gnat1, Gnb1, and Gng1 were measured in adult iPhLPs mice. iPhLPs positive mice mice were identified by genotyping and given 0.1 ml doxycycline (10 mg/ml) by intraperitoneal injection every 24hrs for five days. After the induction period, mice were sacrificed and one retina was used to identify mice that expressed PhLPs while the other eye from the same mouse was used to measure G---protein levels. Even after 5 days of doxycycline injects not all of the animals that were identified as PhLPs positive by genotyping expressed a high enough amount of PhLPs to be detectable by IP. The mice that were PhLPs positive but did not express sufficient PhLPs, referred to as "non---expressors", were used as a negative control (N/Exp in figure  23 ). The results shown in figure  23 compare the change in expression of Gtα1, Gβ1, and Gγ1 normalized to HPRT from the two iPhLPs lines to non---expressors from 2347 (n = 3). Gβ1 and Gγ1 levels do not change significantly compared to control. However, Gtα1 had a 9 fold reduction in the 2339 line and a 6 fold reduction in the 2347 line. The results from this set of experiments is in general agreement with the results from the constitutive line, indicating that the reduction of G---protein levels by CCT inhibition is not dependent on a developmental process.
Discussion
The objective of this project has been to investigate the role of CCT in the biosynthesis and regulation of heterotrimeric G proteins. I set out to build upon the initial data from our lab indicating that the inhibition of CCT affects Gtα1, Gβ1, and Gγ1 at the protein level as well as the mRNA transcript level. The inducible PhLPs (iPhLPs) mouse lines were generated in an attempt to find a connection between CCT and G---protein expression that is dependent on a developmental process. Despite the low frequency of PhLPs induction and the high variability among individual animals I was able to complete one set of experiments. Because the reduction in G---protein levels from these adult animals initially appears to be the same as those seen in younger mice from the constitutive lines, it appears that mature photoreceptors as just as susceptible as developing photoreceptors. However, due to the high variability in PhLPs expression, this experiment will need to be repeated.
PhLPs is a potent inhibitor of CCT, which is responsible for folding a wide variety of proteins with many diverse functions. Based on this, one might think that the most significant effect of PhLPs expression would be triggering of the unfolded protein response (UPR). However, the results of the microarray and Gene Ontology (GO) analysis have indicated that this is not the case. Very few genes are significantly affected by the inhibition of CCT by PhLPs based on the microarray results. Only 160 genes had changes in gene expression that were significant different in either the high (1178) or medium (1054) expressor lines of mice constitutively expressing PhLPs. Out of these 160 genes only 9 genes had expression levels that were decreased by more than 2 fold or increased more than 1.5 fold. Collectively these experiments indicate that CCT plays an essential role in the visual process. The genes that are most heavily impacted by its inhibition are involved in visual perception or cellular organization. Gnat1 stood out in the microarray results because it had the largest decrease in mRNA expression. Despite the fact that these results were strikingly specific, they still offered no direct connection between CCT and Gα.
In the future, it may be prudent to design experiments that connect the resulting changes in gene expression due to CCT inhibition with loss of photoreceptor cells. It will be interesting to see if inducing PhLPs in adult mice will lead to the same degree of photoreceptor death that was seen in the constitutive lines of younger animals. Because many of the same genes participate in numerous biological processes as indicated by the GO analysis, it is possible that the Gα loss due to PhLPs expression causes more significant cell death in developing photoreceptors than in adult photoreceptors. This could be tested by doing functional experiments such as an electroretinogram (ERG) slides and histology experiments using photoreceptors of inducible mice to support the previous findings. This may lead to discovering a connection between CCT and Gα.
EXPERIMENTAL PROCEDURES Generation of PhLPs Transgenic Mice
Three lines of transgenic mice were generated (28)to constitutively express PhLPs in rod photoreceptor cells. To prepare the dominant negative form of phosducin---like protein lacking the first 83 amino acids and containing C---terminal FLAG tag, total RNA was first isolated from the retina of a 129/SV mouse using the Absolutely RNA Miniprep Kit (Stratagene, La Jolla, CA), and the RNA was reverse transcribed using the mouse PhLP gene---specific RT primer 5'---ACT AAA TGA GAC TAC AA with the AccuScript High Fidelity 1st Strand cDNA Synthesis Kit (Stratagene; #200820). A PCR, using the PfuUltra Hotstart PCR Master Mix (Stratagene; #600630), was used to amplify the coding sequence of PhLP from the subsequent cDNA, beginning with the 84th codon, thereby creating Δ1---83 PhLP (PhLPs). At the same time, a SalI site and a Kozak sequence (GCCACCATGG) were added to the 5' end, and a FLAG sequence, followed by a BamHI site and two new stop codons, were added to the 3' end of PhLPs. Because the 84th codon of PhLP happens to be ATG, no additional start codon was needed. The following primers were used during PCR to achieve these changes: forward primer 5'---GAG AGT CGA CGC CAC CAT GGA GCG GCT GAT CAA AAA G and reverse primers 5'---CTT GTC ATC GTC GTC CTT GTA ATC ATC TAT TTC CAG ATC GCT GTC TTC and 5'---GCC TGG ATC CCT ACT ACT TGT CAT CGT CGT CCT TGT AAT C. Two separate PCR reactions were performed to keep the primers from getting too large. Both reactions were done using the same forward primer, whereas the first reaction was done with the first reverse primer shown and the second reaction with the second reverse primer shown. After each reaction, PCR products were run on an agarose gel, and the appropriate product band cut out and purified with the Wizard SV Gel and PCR Clean---Up System (Promega, Madison, WI; A9281). The final PCR product was cloned into the pBAM4.2 vector containing a 4.4 kb mouse rhodopsin promoter and a mouse protamine I polyadenylation sequence (29) . Briefly, both the final PCR product and the pBAM4.2 vector were digested with SalI and BamHI restriction endonucleases, gel purified, and ligated so the Kozak---PhLPs---FLAG sequence would be inserted following the mouse rhodopsin promoter and before the mouse protamine I poly(A) sequence, creating pRhop4.4k---PhLPs. The integrity of the construct was confirmed by sequence analysis, and the final transgene (4.4 kb rhodopsin promoter---Kozak---PhLPs---FLAG---MPI poly(A)) was removed from pRhop4.4k---PhLPs by digestion with restriction endonucleases KpnI and SpeI, gel purified, and used for mouse pronuclear injections at the WVU Transgenic Animal Core Facility. Founder mice carrying PhLPs---FLAG were selected by PCR genotyping of tail genomic DNA using the following primers: forward primer 5'---GTG AAT TGA TTG GCA ATT TTG TTC G and reverse primer 5'---ACT ACT TGT CAT CGT CGT CC.
Three lines of mice constitutively producing PhLPs were generated and designated 1178, 1054, and 1065. Protein expression of PhLPs---FLAG in the retinas was confirmed and quantified by immunoblotting using anti---FLAG antibody. The 1178 line had highest expression and is referred to as the high expressor, 1065 is the low expressor, and 1054 is the middle expressor of PhLPs. Colonies were established and maintained by crossing PhLPs---FLAG mice with 129/SV mice (Charles River, Wilmington, MA). All experiments involving animals were performed according to the procedures approved by the Animal Care and Use Committees of West Virginia University and University of Minnesota.
Generation of the inducible PhLPs---i transgenic mice
In order to control the onset of PhLPs expression and CCT suppression, we have generated transgenic mice with the ability to induce expression of PhLPs (PhLPs---i) using a reverse tetracycline---dependent transactivator (rtTA). Transgenic TRE---Tight---PhLPs---FLAG mice were generated by adding a commercial tetracycline responsive promoter, TRE---Tight (Clontech), to a mouse PhLPs cDNA containing a C---terminal FLAG tag. These transgenic TRE---Tight---PhLPs---FLAG were crossed with opsin---rtTA mice (Tg(opsin---rtTA) +/+), generously provided by Drs. Zack and Campochiaro (Johns Hopkins University). Using this model, six transgenic PhLPs---i lines have been generated at the WVU Transgenic Animal Core Facility. Because the reverse tetracycline---dependent transactivator (rtTA) is under the control of an opsin promoter, progeny of this cross express rtTA in photoreceptors. Following administration of the stable tetracycline analog, doxycycline, the TRE---Tight promoter will drive expression of PhLPs---FLAG in photoreceptors. Doxycycline was administered through drinking water (5 µμg/ml doxycycline + 50 µμg/µμl sucrose for 10 days) and interperitoneal injection (0.1 ml twice a day for 5 days), and was optimized by monitoring PhLPs protein levels through immunoprecipitation (IP) and western blot of α---FLAG. In two of the lines, progeny positive for both transgenes (Tg(PhLPs---i)+/---; Tg(opsin---rtTA) +/---) express amounts of PhLPs comparable to the 1054 (medium PhLPs expressor) constitutive line. Both models allow expression of PhLPs in mature photoreceptors.
